Vaxcyte, Inc.
PCVX • Healthcare
About Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia.
Quality Assessment
Vaxcyte, Inc. is a high-risk healthcare company with a Compass Score of 8. This stock has poor quality metrics and high risk. Not recommended for conservative investors.
Score Breakdown
The Compass Score is based on 6 quality factors identified by academic research.
Click any factor to see detailed metrics
Valuation Metrics
Click any metric for details
Technical Overview
Click any metric for details
Wall Street View
Growth Projections
Financial Health
Click any metric for details
Similar High-Quality Stocks
Important Disclaimer
The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.
Unlock Detailed Metrics
Upgrade to Basic to see the actual financial values behind each quality factor.
- See exact ROA, cash flow ratios, and more
- Unlimited stock lookups
- Export data to CSV
- 7-day free trial included
Cancel anytime